Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum

Rhea-AI Summary

Carisma Therapeutics, a clinical-stage biopharmaceutical company specializing in innovative immunotherapies, has announced its participation in the Stifel 2024 Cell Therapy Forum.

Steven Kelly, President and CEO, will engage in a fireside chat on July 9, 2024, at 9:10 am ET. This session will be available via an audio webcast on the Investor Events section of Carisma's Investor Relations webpage and will remain archived for a period.

News Market Reaction

+2.68%

1 alert

+2.68% News Effect

On the day this news was published, CARM gained 2.68%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

PHILADELPHIA, June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Cell Therapy Forum on Tuesday, July 9^th at 9:10 am ET.

An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.

About Carisma

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com

Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-the-stifel-2024-cell-therapy-forum-302180822.html

SOURCE Carisma Therapeutics Inc.

FAQ

When will Carisma Therapeutics participate in the Stifel 2024 Cell Therapy Forum?

Carisma Therapeutics will participate in the Stifel 2024 Cell Therapy Forum on July 9, 2024.

Who will represent Carisma Therapeutics at the Stifel 2024 Cell Therapy Forum?

Steven Kelly, President and CEO of Carisma Therapeutics, will represent the company at the forum.

What is the stock symbol for Carisma Therapeutics?

The stock symbol for Carisma Therapeutics is CARM.

How can I access the Carisma Therapeutics event at the Stifel 2024 Cell Therapy Forum?

You can access the event via an audio webcast available on the Investor Events section of Carisma's Investor Relations webpage.

Will the Carisma Therapeutics chat at the Stifel 2024 Cell Therapy Forum be available after the event?

Yes, the audio webcast of the chat will be archived for a time following the event.